Stefan is B-FLEXION’s Vice-Chairman, a position he has held since the start of 2021, and a non-executive member of its Board. Prior to this he spent close to a decade as Group Chief Operating Officer and Member of the Board at Waypoint (B-FLEXION's predecessor in name), taking, in that period, operating leadership and helping to drive the strategic development of the group in close cooperation with Mr. Ernesto Bertarelli.
Stefan is Chairman of the Board of Boston Pharmaceuticals, which acquires and transforms innovative molecules into differentiated medicines, and he acts as a Director of Stallergenes-Greer, the worldwide leader in allergy immunotherapy. While under B-Flexion ownership Stefan was the chair of the Board of Affidea – formerly Euromedic – the leading provider of Advanced Diagnostics Imaging and Cancer Care services in Europe.
He joined B-FLEXION from Haniel Group where, over a 16 year period, he gathered extensive experience as the Group's CFO and Member of the Management Board and as General Manager of group affiliates. Stefan started his working career in 1991 at Novartis AG (Basel), holding various positions including a role as Head of Divisional Controlling for the Pharma Division.
He is a Member of the Advisory Board of the Center for Leadership and Value in Society at the University of St. Gallen and a member of the "Schweizer Dialog", an initiative at the same university that aims to build a network of leaders in business and politics that aims to instil sustainable values in society. From 2010 to 2016 he was a member of the Board of Directors of Straumann - a global leader in implant, restorative and regenerative dentistry.
Stefan is Swiss and holds an Economics degree from Basel University. He is married and has two sons.